2022
Thromboelastography-Guided Therapy Enhances Patient Blood Management in Cirrhotic Patients: A Meta-analysis Based on Randomized Controlled Trials
Hartmann J, Dias J, Pivalizza E, Garcia-Tsao G. Thromboelastography-Guided Therapy Enhances Patient Blood Management in Cirrhotic Patients: A Meta-analysis Based on Randomized Controlled Trials. Seminars In Thrombosis And Hemostasis 2022 DOI: 10.1055/s-0042-1757135.Peer-Reviewed Original ResearchPatient blood managementBlood productsAdult patientsAdverse eventsBlood managementIntensive care unit stayIndividual blood productsLess blood productsBlood product useCo-primary outcomesLong-term mortalityFresh frozen plasma unitsRisk of hemorrhageRandomized Controlled TrialsRegistered Systematic ReviewUse of thromboelastographyFrozen plasma unitsBleeding eventsFFP useUnit stayProduct transfusionTerm mortalityCirrhotic patientsCoagulation statusPlatelet useSafety, Tolerability, Pharmacokinetics, and Efficacy of Terlipressin Delivered by Continuous Intravenous Infusion in Patients with Cirrhosis and Refractory Ascites
Bajaj J, Fischer J, Yeramian P, Gavis E, Fagan A, Angeli P, Garcia-Tsao G, Adams J, Markham P. Safety, Tolerability, Pharmacokinetics, and Efficacy of Terlipressin Delivered by Continuous Intravenous Infusion in Patients with Cirrhosis and Refractory Ascites. GastroHep 2022, 2022: 1-8. DOI: 10.1155/2022/5065478.Peer-Reviewed Original ResearchLarge-volume paracentesesRefractory ascitesContinuous intravenous infusionIntravenous infusionAverage steady-state plasma concentrationTreatment-related adverse eventsSteady-state plasma concentrationsML/min/Efficacy of terlipressinInfusion of terlipressinSafety/tolerabilityAdvanced liver cirrhosisPhase 2a trialVolume of ascitesVolume of distributionState plasma concentrationsHepatorenal syndromeVariceal bleedingCirrhotic patientsInpatient periodAdverse eventsLiver cirrhosisIV infusionRelated complicationsAcceptable safety
2019
Emricasan (IDN‐6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension
Garcia‐Tsao G, Fuchs M, Shiffman M, Borg BB, Pyrsopoulos N, Shetty K, Gallegos‐Orozco J, Reddy KR, Feyssa E, Chan JL, Yamashita M, Robinson JM, Spada AP, Hagerty DT, Bosch J. Emricasan (IDN‐6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension. Hepatology 2019, 69: 717-728. PMID: 30063802, PMCID: PMC6587783, DOI: 10.1002/hep.30199.Peer-Reviewed Original ResearchConceptsSevere portal hypertensionPortal hypertensionAlanine aminotransferaseCompensated cirrhosisEnd-stage liver disease (MELD) scoreAspartate aminotransferaseAST/alanine aminotransferaseChild class ALiver Disease scoreOpen-label studyNonserious adverse eventsPortal venous inflowAnti-inflammatory effectsHepatitis C virusSplanchnic vasodilationAdverse eventsHVPG measurementIntrahepatic inflammationPortal pressureBlood pressureCirrhosis etiologyMedian ageNonalcoholic steatohepatitisVenous inflowSignificant changes
2018
Acute kidney injury, but not sepsis, is associated with higher procedure‐related bleeding in patients with decompensated cirrhosis
Hung A, Garcia‐Tsao G. Acute kidney injury, but not sepsis, is associated with higher procedure‐related bleeding in patients with decompensated cirrhosis. Liver International 2018, 38: 1437-1441. PMID: 29393567, PMCID: PMC6072624, DOI: 10.1111/liv.13712.Peer-Reviewed Original ResearchConceptsAcute kidney injuryProcedure-related bleedingKidney injuryPost-procedure bleedingRisk factorsCT scanEnd-stage renal diseaseInfection/sepsisAbnormal coagulation parametersBlood product transfusionLarge-volume paracentesisNon-cirrhotic patientsRetrospective chart reviewOnly independent predictorUnstratified cohortsMELD scoreProduct transfusionAdverse eventsChart reviewPatient characteristicsCirrhosis patientsIndependent predictorsRenal diseaseHemoglobin levelsCoagulation parameters